# Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

> **NCT03138655** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 89 (actual)

## Conditions studied

- Ulcerative Colitis
- Crohn's Disease

## Interventions

- **DRUG:** Vedolizumab

## Key facts

- **NCT ID:** NCT03138655
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-08
- **Primary completion:** 2020-03-31
- **Final completion:** 2020-05-26
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2020-12-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03138655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03138655, "Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03138655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*